12 results on '"Belli R"'
Search Results
2. 74TiP Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
3. 1284P MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
4. Locally advanced non-small cell lung cancer: role of induction chemotherapy in resectable N2 disease
5. A THREE-WEEK SCHEDULE OF GEMCITABINE PLUS CISPLATIN AS INDUCTION CHEMOTHERAPY FOR STAGE III NON-SMALL CELL LUNG CANCER (NSCLC): FINAL RESULTS OF A MONOINSTITUTIONAL PHASE II STUDY
6. GEMCITABINE AND CISPLATIN AS INDUCTION CHEMOTHERAPY IN STAGE IIIAN2/IIIB NON-SMALL CELL LUNG CANCER (NSCLC). A MONO-INSTITUTIONAL PHASE II STUDY WITH A 21 DAYS SCHEDULE.
7. Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
8. A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma
9. LBA61 - Phase II results for single-agent nazartinib (EGF816) in adult patients (pts) with treatment-naive EGFR-mutant non-small cell lung cancer (NSCLC)
10. LBA41 - A double-blind, placebo-controlled, randomized, phase 2 study to evaluate the efficacy and safety of switch maintenance therapy with the anti-TA-MUC1 antibody PankoMab-GEX after chemotherapy in patients with recurrent epithelial ovarian carcinoma
11. Erlotinib Role in Pretreated Egfr Wild Type Caucasian Patients: A Retrospective Observational Study
12. 1346 - Erlotinib Role in Pretreated Egfr Wild Type Caucasian Patients: A Retrospective Observational Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.